16th Jun 2021 11:29
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | Barclays PLC. | |
Company dealt in | WILLIS TOWERS WATSON PLC | |
Class of relevant security to which the | ORD | |
dealings being disclosed relate (Note 2) | ||
Date of dealing | 14 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Class of relevant security: | ORD |
|
| ||
Long | Short | ||||
Number | (%) | Number | (%) | ||
(1) | Relevant securities |
|
|
|
|
1,893,218 | 1.47% | 235,448 | 0.18% | ||
|
|
|
| ||
(2) | Derivatives (other than options): |
|
|
|
|
72,359 | 0.06% | 94,581 | 0.07% | ||
|
|
|
| ||
(3) | Options and agreements to |
|
|
|
|
purchase/sell: | 6,100 | 0.00% | 6,100 | 0.00% | |
|
|
|
| ||
TOTAL: |
|
|
|
| |
1,971,677 | 1.53% | 336,129 | 0.26% | ||
|
|
|
|
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities |
|
| ||||
(2) Derivatives (other than options) |
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total |
|
| ||||
|
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit |
Purchase | 2 | 255.6100 USD |
Purchase | 2 | 256.3600 USD |
Purchase | 4 | 257.1812 USD |
Purchase | 8 | 255.8200 USD |
Purchase | 16 | 255.6212 USD |
Purchase | 18 | 257.4900 USD |
Purchase | 21 | 255.0219 USD |
Purchase | 23 | 255.9060 USD |
Purchase | 36 | 255.3411 USD |
Purchase | 77 | 255.6700 USD |
Purchase | 100 | 255.7000 USD |
Purchase | 100 | 256.1100 USD |
Purchase | 100 | 255.7600 USD |
Purchase | 100 | 255.6500 USD |
Purchase | 155 | 255.6566 USD |
Purchase | 170 | 256.1600 USD |
Purchase | 172 | 255.9424 USD |
Purchase | 181 | 255.8065 USD |
Purchase | 200 | 255.3975 USD |
Purchase | 206 | 256.0987 USD |
Purchase | 218 | 256.0445 USD |
Purchase | 300 | 255.4966 USD |
Purchase | 334 | 256.1218 USD |
Purchase | 400 | 255.8274 USD |
Purchase | 499 | 255.3304 USD |
Purchase | 587 | 255.1279 USD |
Purchase | 798 | 256.0968 USD |
Purchase | 929 | 255.2813 USD |
Purchase | 1,017 | 255.3067 USD |
Purchase | 1,185 | 255.1338 USD |
Purchase | 1,436 | 255.4707 USD |
Purchase | 1,954 | 256.3949 USD |
Purchase | 2,075 | 255.5663 USD |
Purchase | 2,363 | 255.8104 USD |
Purchase | 2,535 | 255.0012 USD |
Purchase | 2,585 | 255.0015 USD |
Purchase | 3,034 | 255.8859 USD |
Purchase | 3,867 | 255.0240 USD |
Purchase | 5,309 | 256.2285 USD |
Purchase | 6,617 | 255.3729 USD |
Purchase | 10,989 | 255.7332 USD |
Purchase | 16,171 | 256.1200 USD |
Sale | 1 | 256.7400 USD |
Sale | 18 | 257.4900 USD |
Sale | 100 | 256.5400 USD |
Sale | 100 | 256.4400 USD |
Sale | 108 | 255.8200 USD |
Sale | 128 | 255.4071 USD |
Sale | 170 | 256.1600 USD |
Sale | 200 | 255.9000 USD |
Sale | 200 | 255.5100 USD |
Sale | 200 | 255.3975 USD |
Sale | 300 | 255.6533 USD |
Sale | 330 | 255.8509 USD |
Sale | 355 | 255.3021 USD |
Sale | 608 | 255.8381 USD |
Sale | 1,158 | 255.9200 USD |
Sale | 1,379 | 255.4701 USD |
Sale | 1,671 | 255.3462 USD |
Sale | 1,876 | 255.8649 USD |
Sale | 1,953 | 255.6060 USD |
Sale | 1,954 | 256.3949 USD |
Sale | 2,685 | 256.1215 USD |
Sale | 3,439 | 256.1214 USD |
Sale | 4,500 | 256.1358 USD |
Sale | 4,555 | 255.1346 USD |
Sale | 4,752 | 256.2500 USD |
Sale | 6,413 | 255.8529 USD |
Sale | 6,841 | 255.4927 USD |
Sale | 7,772 | 256.1200 USD |
Sale | 10,193 | 255.0255 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)
OPEN POSITIONS (Note 1)
Product name | Written or | Number of | Exercise | Type | Expiry |
| purchased | relevant securities | price | date | |
| to which the option | ||||
| or derivative | ||||
| relates | ||||
Put Options | Purchased | -100 | 220.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 100 | 240.0000 | American | Jul 16, 2021 |
Call Options | Purchased | 6,000 | 220.0000 | American | Jul 16, 2021 |
Put Options | Purchased | -6,000 | 200.0000 | American | Jul 16, 2021 |
Notes
1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005461/en/
Copyright Business Wire 2021
Related Shares:
Barclays